Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shiwei Longdanhua Capsule for AECOPD (phlegm-heat obstructing the lung)
ChiCTR2600118759Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Feb 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Shiwei Longdanhua in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Change from baseline in BCSS (breathlessness, cough, and sputum score) at Day 14. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
Shiwei Longdanhua
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ChiCTR2600118759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118759.